Reimagining Biopharma: Precision Medicine, Patients, and Purpose with Takeda CEO-Elect

14 snips

Apr 9, 2026

Julie Kim, CEO-elect of Takeda and longtime biopharma leader, talks precision medicine and AI-driven drug development. She explores how individualized therapies strain current trial and regulatory models. She outlines using AI, robotics, and real-world data to speed R&D and improve access. She also discusses sharpening Takeda’s growth story while keeping a patient-first culture.

Ask episode

AI Snips

Chapters

Books

Transcript

Episode notes

ADVICE

Use AI Automation To Compress Formulation Timelines

Apply AI and automation across later development steps like formulation to cut months of lab work.
Kim describes using AI to screen excipients and robots to run 24/7 tests, boosting efficiency.

INSIGHT

China Offers Speed And Data, Not Just Low Cost

China is now a source of both cost efficiency and rapid clinical innovation, not just low-cost manufacturing.
Kim says faster trials and data in China drive many pharma deals, though geopolitical calibration is needed for FDA acceptance.

INSIGHT

Balance China Speed With FDA Acceptance

Geopolitical shifts force balance between leveraging China and meeting FDA expectations to avoid costly re-dos.
Kim warns excessive Chinese enrollment can prompt FDA pushback requiring repeat phases and negating benefits.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Takeda Pharmaceuticals operates at the intersection of deep scientific innovation and complex global healthcare systems, with a portfolio spanning gastroenterology, oncology, neuroscience, rare diseases, and plasma-derived therapies. CEO-elect Julie Kim joins Yassaman Salas, global co-head of the Healthcare Group within Investment Banking at Goldman Sachs, to discuss the promise of precision medicine, the role of AI and real-world data in accelerating development and access, and how she plans to sharpen Takeda’s growth story while preserving its patient-first, values-driven culture.

This episode was recorded on October 31, 2025.

The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs.

A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs. Disclosures applicable to research with respect to issuers, if any, mentioned herein are available through your Goldman Sachs representative or at http://www.gs.com/research/hedge.html

Goldman Sachs does not endorse any candidate or any political party.

Learn more about your ad choices. Visit megaphone.fm/adchoices